GAMMA Investing LLC Has $571,000 Holdings in Veracyte, Inc. (NASDAQ:VCYT)

GAMMA Investing LLC increased its position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 4,351.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,273 shares of the biotechnology company's stock after acquiring an additional 18,840 shares during the period. GAMMA Investing LLC's holdings in Veracyte were worth $571,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Jones Financial Companies Lllp lifted its stake in Veracyte by 49.7% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 237 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of Veracyte by 1,267.6% during the 1st quarter. Versant Capital Management Inc now owns 930 shares of the biotechnology company's stock worth $28,000 after buying an additional 862 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Veracyte during the 4th quarter worth $64,000. US Bancorp DE lifted its position in shares of Veracyte by 57.4% during the 4th quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company's stock worth $70,000 after buying an additional 647 shares during the last quarter. Finally, Principal Securities Inc. boosted its stake in Veracyte by 34.1% in the fourth quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company's stock valued at $76,000 after buying an additional 485 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Wall Street Zen raised Veracyte from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Craig Hallum initiated coverage on shares of Veracyte in a report on Thursday, March 20th. They set a "buy" rating and a $45.00 price target on the stock. UBS Group lowered their price objective on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Guggenheim cut their target price on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Finally, Needham & Company LLC decreased their target price on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.90.

Veracyte Trading Up 0.2%

VCYT traded up $0.06 during trading on Thursday, reaching $26.82. 687,335 shares of the company's stock were exchanged, compared to its average volume of 911,745. Veracyte, Inc. has a one year low of $19.73 and a one year high of $47.32. The firm has a fifty day moving average price of $29.16 and a two-hundred day moving average price of $35.20. The stock has a market capitalization of $2.10 billion, a PE ratio of 65.42 and a beta of 2.09.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.